-
Dishman Carbogen Amcis receives USFDA approval for new manufacturing facility
The new facility will produce active pharmaceutical ingredients (APIs) and is expected to be operational in early 2024.
-
Dishman Carbogen Amcis announces new partnership with Evotec
The partnership will focus on the development and manufacturing of novel therapies for cancer and other diseases.
-
Dishman Carbogen Amcis reports strong financial results for Q3 FY23
The company reported a 22% increase in revenue and a 15% increase in EBITDA compared to the same period last year.
-
Dishman Carbogen Amcis Limited Announces Q3 FY23 Results
Dishman Carbogen Amcis Limited (NSE: DISHMAN), a leading pharmaceutical and fine chemical company, has announced its financial results for the third quarter (Q3) of fiscal year 2023 (FY23).
-
Dishman Carbogen Amcis Limited Partners with SK pharmteco to Expand Manufacturing Capacity
Dishman Carbogen Amcis Limited (NSE: DISHMAN) has entered into a strategic partnership with SK pharmteco, a leading global CDMO, to expand its manufacturing capacity and enhance its capabilities in the production of active pharmaceutical ingredients (APIs).
-
Dishman Carbogen Amcis Limited Receives US FDA Approval for its Oncology API Manufacturing Facility
Dishman Carbogen Amcis Limited (NSE: DISHMAN) has announced that its oncology API manufacturing facility in Bavla, Gujarat, India, has received approval from the United States Food and Drug Administration (US FDA).
-
Dishman Carbogen Amcis Limited Announces FY23 Q1 Results
The Board of Directors of Dishman Carbogen Amcis Limited at its meeting held on August 02, 2022, has approved the unaudited standalone and consolidated financial results of the Company for the quarter ended June 30, 2022.
-
Dishman Carbogen Amcis Limited Enters into Strategic Partnership with Enzene Biosciences
Dishman Carbogen Amcis Limited and Enzene Biosciences have entered into a strategic partnership to develop and commercialize novel small molecule therapeutics for the treatment of cancer.
-
Dishman Carbogen Amcis Limited Announces Successful Completion of Acquisition of Carbogen Amcis
Dishman Carbogen Amcis Limited has announced the successful completion of the acquisition of Carbogen Amcis, a leading global provider of pharmaceutical services and technologies.
